Long-term persistence in use of statin therapy in elderly patients
Long-term persistence in use of statin therapy in elderly patients
复制标题
DOI：
10.1001/jama.288.4.455
复制
发表时间：
2002-07-24
影响因子：
120.7
通讯作者：
Avorn, J
中科院分区：
文献类型：
--
作者：
Benner, JS;Glynn, RJ;Avorn, J
背景3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂（他汀类）治疗的长期持续性的知识是有限的，因为以前的研究在密切监测的临床试验或其他非代表性的settings.Objective描述在美国老年人群中他汀类治疗的长期持续性的模式和预测因素。回顾性队列研究，包括34501名参加新泽西医疗补助和药物援助老年人和残疾人计划的65岁及以上的患者，在1990年至1998年期间开始他汀类药物治疗，并随访至死亡、退出或12月31日，1999.主要结果测量在治疗的第一年和此后每6个月的每个季度中他汀类药物覆盖的天数比例（PDC）;每个间隔期间次优持续性的预测因素（PDC
Context Knowledge of long-term persistence with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy is limited because previous studies have observed patients for short periods of time, in closely monitored clinical trials, or in other unrepresentative settings.Objective To describe the patterns and predictors of long-term persistence with statin therapy in an elderly US population.Design, Setting, and Patients Retrospective cohort study including 34501 enrollees in the New Jersey Medicaid and Pharmaceutical Assistance to the Aged and Disabled programs who were 65 years of age and older, initiated statin treatment between 1990 and 1998, and who were followed up until death, disenrollment, or December 31, 1999.Main Outcome Measures Proportion of days covered (PDC) by a statin in each quarter during the first year of therapy and every 6 months thereafter; predictors of suboptimal persistence during each interval (PDC